Physician profile
David Mcdowell
NPI 1528303559
$3,182.26
in general payments reported to CMS, 2019-2025
19 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $781 · 2022: $500 · 2023: $454 · 2024: $595 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $960.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $787.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.85 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $165.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $142.80 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $130.67 | 2022-2023 | |
| Abbvie INC. | $112.46 | 2021-2024 | |
| Pfizer INC. | $86.85 | 2021-2024 | |
| Lilly USA, LLC | $67.56 | 2021-2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $66.74 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $35.98 | 2021-2022 | |
| Amarin Pharma, INC. | $29.31 | 2021 | |
| Dexcom, INC. | $25.18 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Mylan Specialty L.P. | $18.12 | 2023 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.65 | 2025 | Caplyta |
| Viatris Specialty LLC | $15.39 | 2025 | Yupelri |
| Amgen INC. | $15.34 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.